Thompson Siegel & Walmsley LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 21.2% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,582 shares of the medical research company’s stock after buying an additional 627 shares during the period. Thompson Siegel & Walmsley LLC’s holdings in Amgen were worth $617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently added to or reduced their stakes in AMGN. Canada Pension Plan Investment Board lifted its position in shares of Amgen by 65.7% in the 2nd quarter. Canada Pension Plan Investment Board now owns 1,706,261 shares of the medical research company’s stock worth $293,869,000 after purchasing an additional 676,300 shares during the period. Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Amgen in the 1st quarter worth approximately $110,402,000. Swiss National Bank lifted its position in shares of Amgen by 26.5% in the 1st quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock worth $432,490,000 after purchasing an additional 551,600 shares during the period. Bank of Nova Scotia lifted its position in shares of Amgen by 414.4% in the 1st quarter. Bank of Nova Scotia now owns 601,862 shares of the medical research company’s stock worth $98,747,000 after purchasing an additional 484,868 shares during the period. Finally, First Eagle Investment Management LLC purchased a new stake in shares of Amgen in the 2nd quarter worth approximately $71,081,000. 78.15% of the stock is owned by institutional investors.
Shares of Amgen Inc. (NASDAQ:AMGN) opened at $169.84 on Wednesday. The firm has a market cap of $122,526.45, a price-to-earnings ratio of 13.42, a PEG ratio of 2.45 and a beta of 1.37. Amgen Inc. has a 52 week low of $138.83 and a 52 week high of $191.10. The company has a quick ratio of 5.72, a current ratio of 6.07 and a debt-to-equity ratio of 1.05.
Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 25th. The medical research company reported $3.27 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The firm had revenue of $5.77 billion for the quarter, compared to analyst estimates of $5.75 billion. Amgen had a net margin of 35.54% and a return on equity of 29.90%. The business’s quarterly revenue was down .7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.02 earnings per share. research analysts forecast that Amgen Inc. will post 12.66 EPS for the current fiscal year.
Amgen announced that its Board of Directors has initiated a share buyback program on Wednesday, October 25th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to repurchase shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Friday, November 17th will be paid a $1.15 dividend. The ex-dividend date is Thursday, November 16th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.71%. Amgen’s payout ratio is currently 41.63%.
Several equities research analysts have recently weighed in on the stock. Argus cut shares of Amgen from a “buy” rating to a “hold” rating and upped their price target for the stock from $175.22 to $195.00 in a research report on Wednesday, November 1st. Zacks Investment Research cut shares of Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Mizuho set a $198.00 price target on shares of Amgen and gave the stock a “buy” rating in a research report on Sunday, October 29th. BMO Capital Markets reaffirmed a “market perform” rating and issued a $198.00 price target on shares of Amgen in a research report on Thursday, October 26th. Finally, Morgan Stanley lowered their price target on shares of Amgen from $196.00 to $193.00 and set an “overweight” rating for the company in a research report on Thursday, October 26th. Thirteen investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $190.03.
TRADEMARK VIOLATION WARNING: This piece was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this piece on another publication, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark legislation. The original version of this piece can be viewed at https://ledgergazette.com/2017/11/22/thompson-siegel-walmsley-llc-grows-holdings-in-amgen-inc-amgn.html.
In other news, Director Carbonnel Francois De sold 4,000 shares of the stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total value of $694,440.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $171.58, for a total transaction of $261,659.50. Following the completion of the sale, the executive vice president now owns 57,631 shares in the company, valued at approximately $9,888,326.98. The disclosure for this sale can be found here. Insiders sold 7,050 shares of company stock worth $1,239,673 in the last quarter. Company insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.